1.
Odi Bruckman
@odibro
$SLGL Hosts Investor Call to Discuss Positive Results from
Twyneo Phase 3 Program in Acne Vulgaris. CC today at 8:… twitter.com/i/web/status/1…
Twyneo Phase 3 Program in Acne Vulgaris. CC today at 8:… twitter.com/i/web/status/1…
2.
Odi Bruckman
@odibro
#PressRelease GENFIT: Positive Phase 2 Results from Study of #Elafibranor in Primary Biliary Cholangitis … twitter.com/i/web/status/1…
Retweet of status by @genfit_pharma
3.
4.
5.
6.
7.
Odi Bruckman
@odibro
$AKCA Announces Its Access and Distribution Strategy for TEGSEDI (inotersen) $IONS $ESRX globenewswire.com/news-release/2…
Odi Bruckman
@odibro
$TXMD Announces Commercial Availability of Imvexxy 4 mcg in the US
Odi Bruckman
@odibro
$VRTX Receives a Positive PBAC Recommendation for Reimbursement of ORKAMBI to Treat Australians Ages Six and Over… twitter.com/i/web/status/1…
Odi Bruckman
@odibro
$BLUE to Present Updated Data for Lenti-D Gene Therapy for Cerebral Adrenoleukodystrophy at SSIEM 2018 Symposium… twitter.com/i/web/status/1…
Odi Bruckman
@odibro
@d4ytrad3 $EDAP Announced FDA Clearance for Focal One for the ablation of prostate tissue globenewswire.com/news-release/2…
8.
9.
10.
11.
Odi Bruckman
@odibro
$AZN FDA Approves TAGRISSO (osimertinib) As 1st-Line Treatment For EGFR-Mutated Non-Small Cell Lung Cancer #NSCLC astrazeneca.com/media-centre/p…
Odi Bruckman
@odibro
$AVEO Announces EUSA Pharma Granted Positive NICE Recommendation for FOTIVDA (tivozanib) as First Line Treatment for Advanced RCC
Odi Bruckman
@odibro
$MNTA and $MYL Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA (aflibercept) globenewswire.com/news-release/2…
Odi Bruckman
@odibro
$ALXN Soliris (Eculizumab) Receives Marketing Authorization in Japan for the Treatment of Patients with Generalize… twitter.com/i/web/status/9…
...but wait! There's more!
1.
fakhright
@fakhright
astaghfirullah peng.krim guaaaaaaaa..............a *salto sambil solat*
